Pharmacological Intervention to Modulate HDL: What Do We Target?

Keywords HDL , pharmaceutical intervention , HDL functionality , HDL subclass , cardiovascular disease Citation Woudberg NJ, Pedretti S, Lecour S, Schulz R, Vuilleumier N, James RW and Frias MA (2018) Pharmacological Intervention to Modulate HDL: What Do We Target? . Front. Pharmacol. 8:989. doi: 10.3389/fphar.2017.00989 Received 23 October 2017 Accepted 22 December 2017 Published 22 January 2018 Volume 8 - 2017 Edited by Lina Badimon, Catalan Institute of Cardiovascular Sciences, Spain Reviewed by Gaetano Santulli, Columbia University, United States; Hiten D. Mistry, University of Nottingham, United Kingdom Updates Check for updates Copyright © 2018 Woudberg, Pedretti, Lecour, Schulz, Vuilleumier, James and Frias. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Miguel A. Frias, miguel.frias@hcuge.ch ; miguel.frias@unige.ch This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.